AstraZeneca Stock Soars 6.14% on AI Data Patent News as Citi Stays Buy
AZN•AstraZeneca shares jumped 6.14% after a peer filed a European patent application covering high-dimensional biological data structures for AI-driven drug discovery. Citi upheld its ‘buy’ rating and existing price target ahead of AstraZeneca’s upcoming second-quarter earnings, reflecting confidence in the company’s late-stage pipeline and revenue growth prospects.
1. Peer AI Patent Sparks AstraZeneca Rally
A peer company filed European patent application No. EP26187897.9 for high-dimensional biological data structures underpinning AI-driven drug discovery platforms. This move fueled a 6.14% gain in AstraZeneca shares alongside similar rallies in biotech peers, highlighting investor enthusiasm for proprietary data layers in life-sciences AI.
2. Citi Reiterates Buy Rating
Ahead of its second-quarter earnings release, Citi reaffirmed a ‘buy’ rating on AstraZeneca and left its price target unchanged. The firm cited expectations for steady revenue growth driven by the company’s late-stage oncology and rare-disease pipeline as key reasons for its positive outlook.
